Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 7Specimen Handling 7tislelizumab 6Cisplatin 6Carboplatin 6atezolizumab 5Pemetrexed 5Bevacizumab 5Platinum 4Interviews as Topic 4Injections 4Educational Status 4Cyclophosphamide 4Biopsy 4fludarabine 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Early Intervention, Educational 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2X-Rays 2Trastuzumab 2Standard of Care 2Radiotherapy 2Radiation 2Practice Guidelines as Topic 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ontruzant × Other solid neoplasm × 30 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡